Rocket Pharmaceuticals

122 articles with Rocket Pharmaceuticals

• Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

  11/15/2021

  Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

• Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data

  11/11/2021

  Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data

• Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference

  11/10/2021

  Rocket Pharmaceuticals, Inc. today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 2:40 p.m. ET.

• Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021

  11/8/2021

  Rocket Pharmaceuticals, Inc. announces that updated data from the ongoing Phase 1 clinical trial of RP-A501 in Danon Disease will be presented at the American Heart Association Scientific Sessions 2021 taking place virtually November 13-15, 2021.

• Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting

  11/4/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces upcoming data presentations at the 63rd American Society of Hematology Annual Meeting taking place virtually and in Atlanta, Georgia from December 11-14, 2021.

• Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

  11/3/2021

  Rocket Pharmaceuticals, Inc. today reports financial results for the quarter ending September 30, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.

• Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

  10/20/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces interim data updates from the RP-L201 Phase 1/2 clinical trial for the treatment of Leukocyte Adhesion Deficiency-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy.

• Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

  10/19/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces data presentations at the 28th Annual Congress of the European Society of Gene & Cell Therapy taking place virtually October 19-22, 2021.

• Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa

  10/7/2021

  Rocket Pharmaceuticals, Inc. today announces that Gaurav Shah, M.D., chief executive officer, will deliver an in-person company presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference virtually and in Carlsbad, CA.

• Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

  9/30/2021

  Rocket Pharmaceuticals to Participate in the Chardan Virtual 5 th Annual Genetic Medicines Conference

• Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021

  9/14/2021

  Rocket Pharmaceuticals, Inc. today announces an oral presentation of previously disclosed data from the ongoing Phase 1 trial of RP-A501 for the treatment of Danon Disease was given at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

• Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021

  9/10/2021

  Rocket Pharmaceuticals, Inc. today announces that previously disclosed data from the ongoing Phase 1 trial of RP-A501 in Danon Disease will be presented in a late-breaking oral presentation at the upcoming Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

• 

  BioSpace Movers & Shakers, Sept. 10

  9/10/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer

  9/7/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces the appointment of Isabel Carmona, J.D., as chief human resources officer and senior vice president.

• Rocket Pharmaceuticals Announces $26.4 Million Private Placement

  8/30/2021

  Rocket Pharmaceuticals, Inc. announces a securities purchase agreement with a fund affiliated with RTW Investments, LP, the Company’s largest shareholder, for the purchase of an aggregate of 812,516 shares of common stock, par value $0.01 per share, at a purchase price of $32.48 per share, the closing price on August 27, 2021, for aggregate gross proceeds of approximately $26.4 million to the Company before offering expenses.

• 

  Clinical Catch-Up: August 16-20

  8/23/2021

  It was another busy week in clinical trial news. Here’s a look.

• Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501

  8/16/2021

  Rocket Pharmaceuticals, Inc. today announces that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Phase 1 clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume.

• 

  Rocket Relaunches Gene Therapy Program as FDA Lifts Clinical Hold

  8/16/2021

  Patient enrollment in the Phase I study will resume, the company announced this morning.

• Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

  8/9/2021

  Rocket Pharmaceuticals, Inc. today reports financial results for the quarter ending June 30, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.

• Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights

  8/3/2021

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, will host a conference call and live audio webcast on Monday, Aug. 9, 2021, at 4:30 p.m. ET to report second quarter 2021 financial results and recent business highlights.